Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 2/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 5/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748374 | 1.00 | CYP2A6 (0.54) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL588130 | 0.92 | CYP2A6 (0.54) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL5143608 | 0.88 | HTR2A (0.46) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL1800067 | 0.85 | METAP1 (0.52) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL16559360 | 0.84 | HTR2A (0.58) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL27844095 | 0.81 | CYP2A6 (0.42) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL27844072 | 0.81 | CYP2A6 (0.42) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| Pyrrolidine SCHEMBL10564943 | 0.81 | HTR2C (0.56) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL12430509 | 0.80 | HTR2A (0.46) | CYP2A6HTR2AHTR2CHTR2BMETAP1 | |
| SCHEMBL15962624 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | NEW YORK UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | NEW YORK UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| CN-113316577-A | GLi1 inhibitors as therapeutic agents | 纽约大学 | 2021-08-27 | — | — | CN | disclosed |
| EP-1741693-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | NAGOYA IND SCIENCE RES INST (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | ZHAN-PLASKET FAN | 2009-12-31 | — | — | US | disclosed |
| US-7576238-B2 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-5436261-A | Adrenergic agonists | ADIR ET COMPAGNIE (FR) | 1995-07-25 | — | — | US | disclosed |
| EP-0635497-A2 | Benzospiroalkene derivatives, process for their preparation and pharmaceutical compostions containing them | ADIR ET COMPAGNIE (FR) | 1995-01-25 | — | — | EP | disclosed |
| EP-0230967-B1 | BENZAZECINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-10-23 | — | — | EP | disclosed |
| US-4957911-A | LEARNING ENHANCEMENT | HOFFMANN-LA ROCHE INC. (US) | 1990-09-18 | — | — | US | disclosed |
| US-4876340-A | Benzazecine derivatives for cognitive and memory functions | HOFFMANN-LA ROCHE INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4749791-A | Benzo[f]quinoline intermediates | HOFFMANN-LA ROCHE INC. (US) | 1988-06-07 | — | — | US | disclosed |
| US-4732979-A | CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1988-03-22 | — | — | US | disclosed |
| EP-0230967-A2 | Benzazecine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-08-05 | — | — | EP | disclosed |
| US-4540705-A | Antidepressant imidazolines and related compounds | STERLING DRUG INC. (US) | 1985-09-10 | — | — | US | disclosed |
| EP-0125410-A2 | Imidazolines and related compounds and preparation thereof | STERLING DRUG INC. (US) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | CYP2A6 4734/4885HTR2A 2682/4885HTR2C 3319/4885 |
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | TDO2, ITPA, TTI2 | CYP2A6 955/4885HTR2A 2668/4885HTR2C 2327/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | CYP2A6 1025/4885HTR2A 3118/4885HTR2C 2996/4885 |
| US-20220009935-A1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | GLI1, GLI2, SHH | CYP2A6 4734/4885HTR2A 2682/4885HTR2C 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.